A focused 35-minute whole body MRI screening protocol for patients with von Hippel-Lindau disease.

Gadolinium Hereditary cancer MRI screening Preventive medicine Whole body MRI von Hippel-Lindau disease

Journal

Hereditary cancer in clinical practice
ISSN: 1731-2302
Titre abrégé: Hered Cancer Clin Pract
Pays: Poland
ID NLM: 101231179

Informations de publication

Date de publication:
2019
Historique:
received: 04 05 2019
accepted: 12 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 7 8 2019
Statut: epublish

Résumé

Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited tumor syndrome. Affected patients develop central nervous system hemangioblastomas and abdominal tumors, among other lesions. Patients undergo an annual clinical screening program including separate magnetic resonance imaging (MRI) of the brain, whole spine and abdomen. Consequently, patients are repeatedly subjected to time-consuming and expensive MRI scans, performed with cumulative Gadolinium injections. We report our experience with a 35-min whole body MRI screening protocol, specifically designed for detection of VHL-associated lesions. We designed an MRI protocol dedicated to the typical characteristics of VHL-associated lesions in different imaging sequences, within the time frame of 35 min. Blank imaging of the abdomen is carried out first, followed by abdominal sequences with Gadolinium contrast. Next, the full spine is examined, followed by imaging of the brain. A single dose of contrast used for abdominal imaging is sufficient for further highlighting of spine- and brain lesions, thus limiting the Gadolinium dosage. We used 1.5 Tesla equipment, dealing with fewer artifacts compared to a 3 Tesla system for spine- and abdominal imaging, while preserving acceptable quality for central nervous system images. In addition, imaging on a 1.5 Tesla scanner is slightly faster. From January 2016 to November 2018, we performed 38 whole body screening MRIs in 18 VHL patients; looking for the most common types of VHL lesions in the abdomen, spine, and brain, both for new lesions and follow-up. The one-step approach MRI examinations lead to 6 surgical interventions for clinically significant or symptomatic hemangioblastomas in the brain and spine. One renal cell carcinoma was treated with radiofrequency ablation. In comparison with previous conventional MRI scans of the same patients, all lesions were visible with the focused protocol. Annual screening in VHL disease can be done in a rapid, safe and sensitive way by using a dedicated whole body MRI protocol; saving MRI examination time and limiting Gadolinium dose.

Sections du résumé

BACKGROUND BACKGROUND
Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited tumor syndrome. Affected patients develop central nervous system hemangioblastomas and abdominal tumors, among other lesions. Patients undergo an annual clinical screening program including separate magnetic resonance imaging (MRI) of the brain, whole spine and abdomen. Consequently, patients are repeatedly subjected to time-consuming and expensive MRI scans, performed with cumulative Gadolinium injections. We report our experience with a 35-min whole body MRI screening protocol, specifically designed for detection of VHL-associated lesions.
METHODS METHODS
We designed an MRI protocol dedicated to the typical characteristics of VHL-associated lesions in different imaging sequences, within the time frame of 35 min. Blank imaging of the abdomen is carried out first, followed by abdominal sequences with Gadolinium contrast. Next, the full spine is examined, followed by imaging of the brain. A single dose of contrast used for abdominal imaging is sufficient for further highlighting of spine- and brain lesions, thus limiting the Gadolinium dosage. We used 1.5 Tesla equipment, dealing with fewer artifacts compared to a 3 Tesla system for spine- and abdominal imaging, while preserving acceptable quality for central nervous system images. In addition, imaging on a 1.5 Tesla scanner is slightly faster.
RESULTS RESULTS
From January 2016 to November 2018, we performed 38 whole body screening MRIs in 18 VHL patients; looking for the most common types of VHL lesions in the abdomen, spine, and brain, both for new lesions and follow-up. The one-step approach MRI examinations lead to 6 surgical interventions for clinically significant or symptomatic hemangioblastomas in the brain and spine. One renal cell carcinoma was treated with radiofrequency ablation. In comparison with previous conventional MRI scans of the same patients, all lesions were visible with the focused protocol.
CONCLUSIONS CONCLUSIONS
Annual screening in VHL disease can be done in a rapid, safe and sensitive way by using a dedicated whole body MRI protocol; saving MRI examination time and limiting Gadolinium dose.

Identifiants

pubmed: 31384339
doi: 10.1186/s13053-019-0121-9
pii: 121
pmc: PMC6664785
doi:

Types de publication

Journal Article

Langues

eng

Pagination

22

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Fam Cancer. 2012 Sep;11(3):387-94
pubmed: 22426863
Radiol Med. 2019 Mar;124(3):218-233
pubmed: 30430385
AJNR Am J Neuroradiol. 2003 Sep;24(8):1570-4
pubmed: 13679272
Radiology. 2015 Jul;276(1):228-32
pubmed: 25942417
Clin Cancer Res. 2017 Jun 15;23(12):e68-e75
pubmed: 28620007
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
Hered Cancer Clin Pract. 2018 Jan 05;16:2
pubmed: 29312473
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Head Neck. 2016 Apr;38 Suppl 1:E673-9
pubmed: 25867206
Fam Cancer. 2005;4(1):37-42
pubmed: 15883708
Radiographics. 2008 Jan-Feb;28(1):65-79; quiz 323
pubmed: 18203931
Lancet. 2003 Jun 14;361(9374):2059-67
pubmed: 12814730
J Neurosurg. 2003 Jan;98(1):82-94
pubmed: 12546356
Radiographics. 2018 May-Jun;38(3):849-866
pubmed: 29601266
Ophthalmologe. 2007 Feb;104(2):119-26
pubmed: 17235573

Auteurs

Anne-Marie Vanbinst (AM)

1Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Carola Brussaard (C)

1Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Evelynn Vergauwen (E)

2Department of Neurosurgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

Vera Van Velthoven (V)

2Department of Neurosurgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

Robert Kuijpers (R)

3Department of Ophthalmology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Olaf Michel (O)

4Department of Otorhinolaryngology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Ina Foulon (I)

4Department of Otorhinolaryngology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Anna C Jansen (AC)

5Department of Pediatrics, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Bieke Lefevere (B)

6Department of Psychology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Susanne Bohler (S)

6Department of Psychology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Kathelijn Keymolen (K)

7Department of Genetics, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Johan de Mey (J)

1Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Dirk Michielsen (D)

8Department of Urology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Corina E Andreescu (CE)

9Department of Endocrinology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Sven Gläsker (S)

2Department of Neurosurgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

Classifications MeSH